Chih-Hsin Yang - JoVE Visualize

Showing results (201-210 of 324) with videos related to

Pageof 33

Sort By:

British Journal of Clinical Pharmacology|January 31, 2018

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinibKarthick Vishwanathan, Paul A Dickinson, Karen So, et al.

Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 13, 2019

Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unitEmily Han-Chung Hsiue, Pei-Lin Lee, Yung-Hsuan Chen, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityPeter Ballard, James W T Yates, Zhenfan Yang, et al.

The Patient|November 28, 2017

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.

Investigational New Drugs|March 9, 2023

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 studyJames Chih-Hsin Yang, Wu-Chou Su, Chao-Hua Chiu, et al.

Therapeutic Advances in Medical Oncology|November 3, 2022

Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinomaChia-Ling Chang, Min-Shu Hsieh, Jin-Yuan Shih, et al.

Lung Cancer (Amsterdam, Netherlands)|June 16, 2019

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trialsMartin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final AnalysisChong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.

Journal of the National Cancer Institute|April 5, 2017

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2018

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung CancerYi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.

Pageof 33

Showing results (201-210 of 324) with videos related to

Sort By:

Pageof 33

British Journal of Clinical Pharmacology|January 31, 2018

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinibKarthick Vishwanathan, Paul A Dickinson, Karen So, et al.

Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 13, 2019

Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unitEmily Han-Chung Hsiue, Pei-Lin Lee, Yung-Hsuan Chen, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityPeter Ballard, James W T Yates, Zhenfan Yang, et al.

The Patient|November 28, 2017

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.

Investigational New Drugs|March 9, 2023

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 studyJames Chih-Hsin Yang, Wu-Chou Su, Chao-Hua Chiu, et al.

Therapeutic Advances in Medical Oncology|November 3, 2022

Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinomaChia-Ling Chang, Min-Shu Hsieh, Jin-Yuan Shih, et al.

Lung Cancer (Amsterdam, Netherlands)|June 16, 2019

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trialsMartin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final AnalysisChong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.

Journal of the National Cancer Institute|April 5, 2017

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalChee Khoon Lee, Lucy Davies, Yi-Long Wu, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2018

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung CancerYi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.

Pageof 33